Emflaza
Apr 18, 2017
Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill
Novartis gets second CAR-T candidate FDA ‘breakthrough’ tag As the battle between Swiss major Novartis and biotech rival Kite Pharma heats up to be the first to market a CAR-T cancer med, the Big Pharma has been handed its second FDA ‘breakthrough’ tag for its eagerly awaited JULIET trial. This latest label, which c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
